FDA In Brief
This article was originally published in The Rose Sheet
Executive Summary
OTC drug labeling: FDA's toll-free MedWatch number will be required on all non-monograph OTC drug products, effective April 22, 2005, agency announces. Published April 22 in the Federal Register, the proposal recommends the statement be placed in the "Warnings" section of the Drug Facts panel, under the "Stop Use and Ask a Doctor If" subheading. FDA is recommending that the side effects statement first direct consumers to consult a doctor for medical advice if side effects occur. The labeling addition is required under Best Pharmaceuticals for Children Act, which became law in 2002. The agency estimates 522 OTCs will be subject to the rule, and predicts OTC drug manufacturers will incur a one-time cost of $1.2 mil.-$3.7 mil., depending upon the number of affected SKUs...
You may also be interested in...
Skin Protectant Final Rule Allows Cross-Monograph Ingredient Combinations
The Skin Protectant Final Monograph covering products for minor cuts, scrapes, burns, chapped skin and lips, poison ivy, poison oak, poison sumac and insect bites allows for certain cross-monograph ingredient combinations, according to the rule published in the 1Federal Register June 4
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle